Skip to main content

Table 2 Occurrence of most common imbalances in different epithelial neoplasias by CGH

From: Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data

Regional imbalance

Most frequent*

Above background

Putative targets**

enh(1q)

occuring in most carcinoma types

Breast, ovary, HCC, cervix, NPC, MEL, endometrial, vulva

Gastric, CRC, HCC, HNSCC, NSCLC, ES, RCC, bladder, PAC, SCLC, SQS

ABL2, ETV3

dim(3p)

HNSCC, NSCLC, cervix, ES, RCC, NE, MEL (whole chr. 3), SCLC, vulva, SQS

Gastric, PAC

FHIT, MLH1

enh(3q)

maxima at 3q26q27 (except 3q25 in NPC)

Ovary, HNSCC, NSCLC, cervix, ES, NPC, SCLC, endometrial, vulva, SQS

Gastric, RCC, PAC

BCL6, PIK3CA

dim(4q)

frequently whole chromosome

Ovary, HCC, NSCLC, cervix, ES, bladder, cholangio, SCLC

Gastric, CRC, HNSCC, RCC, PAC,

PRDM5

enh(5p)

Thyroid, NSCLC, cervix,

Gastric, ovary, CRC, HCC, HNSCC, ES, bladder, NE, PAC, cholangio, vulva

CDH6, TERT

dim(5q)

Ovary, NSCLC,

Prostate, gastric, HNSCC, ES, bladder, cholangio,

APC, MCC

enh(6p)

HCC, MEL

Ovary, NSCLC, cervix, ES, bladder, cholangio, SCLC, vulva

E2F3, ID4

dim(6q)

maxima at 6q16q21 or 6q24q27

Prostate, RCC, MEL

Ovary, HCC, NSCLC, cervix, bladder, NE, PAC, cholangio, SCLC

CCNC

enh(7)

frequently whole 7, mostly max. on 7q

Prostate, thyroid, ES, RCC

Gastric, ovary, CRC, HCC, HNSCC, bladder, MEL, PAC (7p>7q), cholangio (7p>7q)

7p: EGFR 7q: ABCB1, MET

dim(8p)

Breast, prostate, CRC, HCC

Ovary, HNSCC, NSCLC, ES, RCC, bladder, PAC, SCLC, vulva

DLC1, MSR1, N33

enh(8q)

ubiquitously high (exception NE and thyroid)

Breast, prostate, ovary, CRC, HCC, HNSCC, NSCLC, ES, RCC, bladder, MEL, PAC, cholangio, endometrial, vulva

Cervix, NPC, SCLC, SQS

MYC

dim(9p)

9p or whole 9

HNSCC, bladder, PAC, SQS

Gastric, NSCLC, ES, RCC, NPC, MEL, SCLC

ARF, CDKN2A

enh(11q13)

frequently distinct (high-level) gain

HNSCC

Breast, gastric, ovary, NSCLC, ES, NPC, bladder, MEL, PAC, cholangio

CCND1, FGF3

dim(11q23qter)

NPC, NE, vulva

Breast, HNSCC, cervix, ES, MEL, SCLC

ATM (11q22), (LOH11CR2 A, TSG11)

enh(12p)

frequently whole 12; slight max. on 12p

NPC

Ovary, CRC, HNSCC, NSCLC, ES, RCC, PAC, vulva

12p: CDK2, CDK4, GLI, KRAS 12q: MDM2

dim(13q)

mostly 13q14q21

Prostate, HCC, thyroid, bladder, NE, PAC, SCLC, endometrial

Breast, gastric, ovary, HNSCC, NSCLC, cervix, ES, RCC, NPC (max. at 13q31), MEL, CRC, vulva

BRCA2, RB1, STARD13

dim(16q)

Breast, NPC

Prostate, gastric, HCC, SCLC

CDH1, ATBF1

dim(17p)

Breast, gastric, CRC, cholangio, SCLC

Ovary, HCC, NSCLC, cervix, ES, RCC, NPC, bladder, PAC, SQS

TP53

enh(17q)

Breast, gastric, bladder, NE, PAC, cholangio, SCLC, SQS

HCC, HNSCC, NSCLC, cervix, ES, renal, NPC

ERBB2

dim(18q)

Gastric, ovary, CRC, HNSCC, PAC, SQS

HCC, NSCLC, cervix, renal, bladder, cholangio

DCC, SMAD4

enh(19q)

NE, SCLC

Breast, CRC, PAC, vulva

AKT2, BAX

enh(20q)

Gastric, CRC, thyroid, bladder, NE, PAC, cholangio

Breast, HCC, cervix, ES, renal, MEL, SCLC, vulva

STK15/AuroraA

  1. Please refer to table 1 for abbreviations. * "most frequent" lists entities in which the aberration belongs to the 3 most frequent imbalances of the specified quality (enh = gain, dim = loss; bold if most frequent change in entity). Entities are sorted according to the total number of included cases. Chromosomal regions 1p, 21, 22, X and Y were omitted due to differences in reporting (e.g. exclusion of regions prone to errors in chromosomal CGH analysis). ** Listed are some examples of genes with oncogene (for gain regions) or tumor suppressor (for loss regions) function. However, a large number of possible target genes as well as structural features may exist for each region.